% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:837424,
      author       = {Galldiks, Norbert and Kocher, Martin and Langen,
                      Karl-Josef},
      title        = {{P}seudoprogression after glioma therapy: an update},
      journal      = {Expert review of neurotherapeutics},
      volume       = {17},
      number       = {11},
      issn         = {1744-8360},
      address      = {Abingdon},
      publisher    = {Taylor $\&$ Francis Group},
      reportid     = {FZJ-2017-06349},
      pages        = {1109-1115},
      year         = {2017},
      abstract     = {Introduction: Initial diagnostics and follow-up of gliomas
                      is usually based on contrast-enhanced MRI. However, the
                      capacity of standard MRI to differentiate neoplastic tissue
                      from posttherapeutic effects such as pseudoprogression is
                      limited. Advanced neuroimaging methods may provide relevant
                      additional information, which allow for a more accurate
                      diagnosis especially in clinically equivocal situations.
                      This review article focuses predominantly on PET using
                      radiolabeled amino acids and advanced MRI techniques such as
                      perfusion-weighted imaging (PWI) and summarizes the efforts
                      of these methods regarding the identification of
                      pseudoprogression after glioma therapy.Areas covered: The
                      current literature on pseudoprogression in the field of
                      brain tumors, with a focus on gliomas is summarized. A
                      literature search was performed using the terms
                      ‘pseudoprogression’, ‘temozolomide’,
                      ‘glioblastoma’, ‘PET’, ‘PWI’,
                      ‘radiochemotherapy’, and derivations thereof.Expert
                      commentary: The present literature provides strong evidence
                      that PWI MRI and amino acid PET can be of great value by
                      providing valuable additional diagnostic information in
                      order to overcome the diagnostic challenge of
                      pseudoprogression. Despite various obstacles such as the
                      still limited availability of amino acid PET and the lack of
                      standardization of PWI, the diagnostic improvement probably
                      results in relevant benefits for brain tumor patients and
                      justifies a more widespread use of these diagnostic tools.},
      cin          = {INM-4 / INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-3-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28862482},
      UT           = {WOS:000414154300006},
      doi          = {10.1080/14737175.2017.1375405},
      url          = {https://juser.fz-juelich.de/record/837424},
}